OUR RESEARCH PARTNERS THE ALZHEIMER’S GENOME PROJECT The Alzheimer’s Genome Project (AGP) launched in 2005 to advance the genetic work to identify the origins and progression of Alzheimer’s Disease. The AGP is using genomic analytic tools to create and mine databases of the genetic codes of tens of thousands of individuals to identify which variants impact the risk of Alzheimer’s or its presentation. Phase I identified more than 100 new gene variants implicated in Alzheimer’s risk. Phase II used wet lab projects to identify which pathways play a role for these genes, including amyloid beta protein generation, tangle formation, the regulation of planned cell death, and more. Phase III is now being carried out in parallel to Phase II, and includes sequencing the genes of both early-onset and late-onset families. Gene regulation is emerging as a key question because it can change as an organism ages and in response to environment. These tools offer new opportunities for understanding and intervening in Alzheimer’s Disease.
Dr. Rudy Tanzi Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School; Director of the Genetics & Aging Research Unit Vice Chair of Neurology Massachusetts General Hospital. Chairman of Cure Alzheimer's Fund Leadership Group.
PATHOGENIC MECHANISMS IN ALZHEIMER’S DISEASE
Dr George S Bloom Professor of Biology, Cell Biology and Neuroscience University of Virginia
7
Research in the Bloom Laboratory is focused on the earliest steps that cause Alzheimer’s Disease (AD), including cognitive decline and abnormal structures in the brain. The goal of the Laboratory is to define the biochemical processes that connect these things, and leverage our findings to develop more effective therapeutic and diagnostic tools. One of our discoveries was that memantine, an FDA-approved drug for mild and temporary symptom relief for advanced AD, might prevent or delay symptoms if provided to patients at risk of AD beginning many years before the symptomatic phase of the disease typically begins.
